6 Big Pharma Companies Left To Report September Quarterly Figures

The following companies have reported their results for the September quarter:

• Abbott Laboratories ABT reported adjusted EPS of $0.59 on revenue of $5.3 billion. While EPS topped by a penny, revenue came in line.
• Eli Lilly and Co LLY reported adjusted EPS of $0.88, revenue of $5.19 billion and missed Street estimates.
• Merck & Co., Inc. MRK reported GAAP EPS of $0.78 and adjusted EPS of $1.07 on revenue of $10.5 billion. Both EPS and revenue topped estimates.
• Novartis AG (ADR) NVS reported core EPS of $1.23 and net sales of $12.13 billion. While EPS topped estimates, revenue fell shy of expectations.

Related Link: Citi Starts Calithera Biosciences At Sell On Cash Burn And Lack Of Near-Term Catalysts

The following companies have yet to announce September quarter results:

• AstraZeneca plc (ADR) AZN is scheduled to disclose its results on November 10. Analysts expect EPS of $0.74 on revenue of $5.91 billion.
• Bristol-Myers Squibb Co BMY is slated to provide results on Thursday. Analysts expect EPS of $0.65 on revenue of $4.79 billion.
• GlaxoSmithKline plc (ADR) GSK will announce its results on Wednesday. The Street is looking for an EPS of $0.74 on revenue of $8.86 billion.
• Pfizer Inc. PFE is scheduled to report on November 1. The Street estimates EPS of $0.62 on revenue of $13.05 billion.
• Sanofi SA (ADR) SNY announces results on Friday. Analysts expect EPS of $0.85 and revenue of $10.69 billion.
• Shire PLC (ADR) SHPG is planning to announce results on November 1. The Street is looking for an EPS of $3.20 and revenue of $3.56 billion.

Full ratings data available on Benzinga Pro.